This is the standing evidence sheet for Abbott Laboratories (ABT): the yardsticks BullScope computes from official SEC filings and market prices. It refreshes whenever a new edition of our research is published, and it is impersonal by design, every reader sees the same page. Nothing here is investment advice; it is the evidence, organized.
The price tag: what buyers pay per dollar of profit
Today the market pays about $27.8 for each $1 of Abbott Laboratories’s annual profit (a price-to-earnings ratio of 27.8). Across its own past decade the typical price tag was 27.5, which puts today at roughly the 52th percentile of the company’s own history.
The tape: what the stock itself has done
- Last price: $100.51 (end-of-day market data as of the edition date · methodology) · 23% below its 52-week high
- Past 6 months: +9.6% · past 12 months: -22.4%
- Day-to-day temperament: jumpy (annualized volatility 27%)
The filed record: straight from the annual reports
| Fiscal year | Revenue | Growth | Operating margin | EPS |
|---|---|---|---|---|
| FY2021 | $43.1B | +24.5% | 19.6% | $3.94 |
| FY2022 | $43.7B | +1.3% | 19.2% | $3.91 |
| FY2023 | $40.1B | -8.1% | 16.2% | $3.26 |
| FY2024 | $42.0B | +4.6% | 16.3% | $7.64 |
| FY2025 | $44.3B | +5.7% | 18.2% | $3.72 |
The road ahead: filed results vs published expectations
| FY2023A | FY2024A | FY2025A | FY2026E | FY2027E | FY2028E | |
|---|---|---|---|---|---|---|
| Net sales ($B) | 40.1 | 42.0 | 44.3 | 52.0 to 56.0 | 55.0 to 62.0 | 57.5 to 67.0 |
| Net sales growth (%) | – | +4.7 | +5.5 | 17.0 to 26.0 | 6.0 to 11.0 | 4.8 to 8.0 |
| Operating margin (%) | 16.2 | 16.3 | 18.2 | 15.5 to 17.0 | 16.0 to 18.0 | 17.0 to 19.0 |
| Diluted EPS ($) | 3.26 | 7.64 | 3.72 | 2.88-3.48 | 3.10 to 4.20 | 3.50 to 5.00 |
Columns marked A are actual filed results; E columns are the published consensus ranges the current price is being weighed against.
The four gauges: from the latest edition
BullScope coverage of Abbott Laboratories
- Abbott’s Scorecard: What the Call Promised, What the Filings Show, and Where the Gap Lives
- Abbott’s Split Personality: Revenue Climbs 14%, the Stock Falls Anyway
- Abbott Is Beating Its Targets. The Stock Is Down 23%. The Gap Is the Story.
- Abbott’s Split Screen: One Business Surging, One Shrinking, and a Stock Priced Somewhere in Between
Read the full report on Abbott Laboratories in the BullScope Terminal → It opens with this company loaded.
Edition date: 2026-10-22. This page updates when a new edition is published. Sources: SEC EDGAR filings, Nasdaq prices; computed by BullScope’s published methodology.
